FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955403780> ?p ?o ?g. }

• W2955403780 abstract "Cyclin-dependent kinase 12 (CDK12) is a transcription-associated protein that plays a critical role in DNA damage response, splicing, pre-mRNA processing and is crucial for maintaining genomic stability. CDK12 associated with Cyclin K (CycK) regulates transcription elongation by phosphorylating RNA polymerase II (RNAP II) at Serine 2 (pS2) in the C-terminal domain (CTD). Overexpression of CDK12 in various tumor types suggests the possibility that CDK12 has oncogenic properties, similarly to other transcription-associated kinases. Considering its critical role in transcription and RNA processing, CDK12 is emerging as a potential therapeutic target for cancer. Multiple series of potent and selective CDK12 covalent inhibitors were identified by structure-guided and iterative medicinal chemistry approaches. Early lead compounds were optimized towards achieving high on target potency with good selectivity and desirable drug like properties including pharmacokinetic profile to achieve anti-tumour activity. Optimization of early lead compounds from two distinct chemical series resulted in very potent and highly selective CDK12 covalent inhibitors with desirable oral bioavailability. The covalent mode of action for these biochemically potent compounds has been confirmed by CDK12 target engagement assay in the cellular context. These selective inhibitors showed significant anti-proliferative activity in TNBC and other cancer cell lines including those harbouring ETS fusion. Importantly, cell killing is observed in cancer cells but not in normal cells (RWPE1) with short time (2h) and long-time (72h) exposure of these compounds. Anti-proliferative activity is well correlated with the inhibition of pS2 and down-regulation of a number of DNA damage response genes including BRCA1, RAD51, ATM and FANCI. Consistent with the inhibition of genes involved in DNA damage repair, a highly synergistic anti-proliferative activity was observed when treated in combination with cisplatin and PARP inhibitors. Based on the robust efficacy as a single agent in a TNBC mouse xenograft model with one of the optimized leads, the preclinical candidate exhibiting a greater degree of selectivity is being evaluated for efficacy and tolerability in relevant preclinical models. Citation Format: Ramulu Poddutoori, Sujatha Rajagopalan, Subhendu Mukherjee, Sivapriya Marappan, Samiulla D. S., Sasirekha Sivakumar, Shilpa S Nayak, Ravindra M V, Devaraja TS, Srinivas Kondela, Suraj Tgore, Amit A Dhudashiya, Charamanna K. B, Aravind A B, Amith A, Pavithra S, Hema Sankar Pathange, Thomas Antony, Mahaboobi Jaleel, Sanjeev Giri, Girish Daginakatte, Kavitha Nellore, Shekar Chelur, Murali Ramachandra, Susanta Samajdar. Pharmacological characterization of a preclinical candidate covalently inhibiting CDK12 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4418." @default.
• W2955403780 created "2019-07-12" @default.
• W2955403780 creator A5003754862 @default.
• W2955403780 creator A5007908300 @default.
• W2955403780 creator A5020172528 @default.
• W2955403780 creator A5021203577 @default.
• W2955403780 creator A5024438197 @default.
• W2955403780 creator A5024745062 @default.
• W2955403780 creator A5029908764 @default.
• W2955403780 creator A5030358136 @default.
• W2955403780 creator A5034729950 @default.
• W2955403780 creator A5036297832 @default.
• W2955403780 creator A5038266306 @default.
• W2955403780 creator A5039885523 @default.
• W2955403780 creator A5050147564 @default.
• W2955403780 creator A5065643058 @default.
• W2955403780 creator A5065784113 @default.
• W2955403780 creator A5066740338 @default.
• W2955403780 creator A5069351991 @default.
• W2955403780 creator A5074867808 @default.
• W2955403780 creator A5075026726 @default.
• W2955403780 creator A5080322198 @default.
• W2955403780 creator A5082709838 @default.
• W2955403780 creator A5084429791 @default.
• W2955403780 creator A5088230644 @default.
• W2955403780 creator A5088934142 @default.
• W2955403780 creator A5091192249 @default.
• W2955403780 date "2019-07-01" @default.
• W2955403780 modified "2023-09-26" @default.
• W2955403780 title "Abstract 4418: Pharmacological characterization of a preclinical candidate covalently inhibiting CDK12" @default.
• W2955403780 doi "https://doi.org/10.1158/1538-7445.sabcs18-4418" @default.
• W2955403780 hasPublicationYear "2019" @default.
• W2955403780 type Work @default.
• W2955403780 sameAs 2955403780 @default.
• W2955403780 citedByCount "0" @default.
• W2955403780 crossrefType "proceedings-article" @default.
• W2955403780 hasAuthorship W2955403780A5003754862 @default.
• W2955403780 hasAuthorship W2955403780A5007908300 @default.
• W2955403780 hasAuthorship W2955403780A5020172528 @default.
• W2955403780 hasAuthorship W2955403780A5021203577 @default.
• W2955403780 hasAuthorship W2955403780A5024438197 @default.
• W2955403780 hasAuthorship W2955403780A5024745062 @default.
• W2955403780 hasAuthorship W2955403780A5029908764 @default.
• W2955403780 hasAuthorship W2955403780A5030358136 @default.
• W2955403780 hasAuthorship W2955403780A5034729950 @default.
• W2955403780 hasAuthorship W2955403780A5036297832 @default.
• W2955403780 hasAuthorship W2955403780A5038266306 @default.
• W2955403780 hasAuthorship W2955403780A5039885523 @default.
• W2955403780 hasAuthorship W2955403780A5050147564 @default.
• W2955403780 hasAuthorship W2955403780A5065643058 @default.
• W2955403780 hasAuthorship W2955403780A5065784113 @default.
• W2955403780 hasAuthorship W2955403780A5066740338 @default.
• W2955403780 hasAuthorship W2955403780A5069351991 @default.
• W2955403780 hasAuthorship W2955403780A5074867808 @default.
• W2955403780 hasAuthorship W2955403780A5075026726 @default.
• W2955403780 hasAuthorship W2955403780A5080322198 @default.
• W2955403780 hasAuthorship W2955403780A5082709838 @default.
• W2955403780 hasAuthorship W2955403780A5084429791 @default.
• W2955403780 hasAuthorship W2955403780A5088230644 @default.
• W2955403780 hasAuthorship W2955403780A5088934142 @default.
• W2955403780 hasAuthorship W2955403780A5091192249 @default.
• W2955403780 hasConcept C101762097 @default.
• W2955403780 hasConcept C104317684 @default.
• W2955403780 hasConcept C121608353 @default.
• W2955403780 hasConcept C138885662 @default.
• W2955403780 hasConcept C150194340 @default.
• W2955403780 hasConcept C179926584 @default.
• W2955403780 hasConcept C184235292 @default.
• W2955403780 hasConcept C185592680 @default.
• W2955403780 hasConcept C41895202 @default.
• W2955403780 hasConcept C502942594 @default.
• W2955403780 hasConcept C54355233 @default.
• W2955403780 hasConcept C55493867 @default.
• W2955403780 hasConcept C64350747 @default.
• W2955403780 hasConcept C86339819 @default.
• W2955403780 hasConcept C86803240 @default.
• W2955403780 hasConcept C95444343 @default.
• W2955403780 hasConcept C96232424 @default.
• W2955403780 hasConceptScore W2955403780C101762097 @default.
• W2955403780 hasConceptScore W2955403780C104317684 @default.
• W2955403780 hasConceptScore W2955403780C121608353 @default.
• W2955403780 hasConceptScore W2955403780C138885662 @default.
• W2955403780 hasConceptScore W2955403780C150194340 @default.
• W2955403780 hasConceptScore W2955403780C179926584 @default.
• W2955403780 hasConceptScore W2955403780C184235292 @default.
• W2955403780 hasConceptScore W2955403780C185592680 @default.
• W2955403780 hasConceptScore W2955403780C41895202 @default.
• W2955403780 hasConceptScore W2955403780C502942594 @default.
• W2955403780 hasConceptScore W2955403780C54355233 @default.
• W2955403780 hasConceptScore W2955403780C55493867 @default.
• W2955403780 hasConceptScore W2955403780C64350747 @default.
• W2955403780 hasConceptScore W2955403780C86339819 @default.
• W2955403780 hasConceptScore W2955403780C86803240 @default.
• W2955403780 hasConceptScore W2955403780C95444343 @default.
• W2955403780 hasConceptScore W2955403780C96232424 @default.
• W2955403780 hasLocation W29554037801 @default.
• W2955403780 hasOpenAccess W2955403780 @default.
• W2955403780 hasPrimaryLocation W29554037801 @default.
• W2955403780 hasRelatedWork W1549671162 @default.
• W2955403780 hasRelatedWork W1591296341 @default.

• next